Blog

0 comments on “25 more drugs come under price control- Are we missing out out on an integrated approach?”

25 more drugs come under price control- Are we missing out out on an integrated approach?

NEW DELHI: There’s good news for patients. Drug pricing regulator NPPA announced cap on prices of over 25 drugs, including painkillers and antibiotics, which will lead to reduction in their costs over the next few weeks. 

The price regulator in a notification issued on December 10, fixed prices of formulations which join a list of 348 essential medicines that were placed under price control. The new drugs on which caps were issued include commonly-used antibiotics and painkillers, as well as medicines used for treating cancer and skin disorders.

The NPPA notification mentions a total of 52 drugs, including those with specific dosage strengths which were till now not under the purview. The latest addition brings the total market size of medicines under price control to nearly Rs 125 crore, according to market research firm AIOCD AWACS. The wide-ranging price cuts will impact both domestic and foreign companies. 

The NPPA notification, an industry expert explained, also includes price changes which will be extended on dosage strengths of molecules which were till now not under price control. It said it has fixed/revised the prices in respect of 52 formulation packs — both ceiling and retail price packs under DPCO, 2013. Price caps on some of these drugs only apply to specific companies, it added 

Earlier efforts by the NPPA to bring down prices of essential drugs for diseases like cancer, have been strongly opposed. In July, the NPPA in a rare invocation of the lesser-used provision had fixed prices of 50 antidiabetic and cardiovascular medicines. This was the first time that the government had brought drugs, outside the national list of essential medicines, under price control. 

The move had triggered of a series of protests and lawsuits from the industry against the drug pricing regulator, as they feared more such action. 

Finally, in September this year the government had withdrawn certain powers of the drug pricing regulator that allowed it to cap prices of widely-prescribed anti-diabetes, cancer, HIV, tuberculosis and cardiac medicines. 

0 comments on “1.1 Million new cases in cancer each year. is it an epidemic??”

1.1 Million new cases in cancer each year. is it an epidemic??

Logo

11 lakh Cancer cases in India every year: Govt

About 11 lakh Cancer cases are occurring in India every year, the Lok Sabha was informed today.
Replying to a question, Minister of State for Health and Family Welfare Shripad Yesso Naik said, it is estimated that about 11 lakh Cancer cases are occurring every year (incidence) in India, as per the estimates of Indian Council of Medical Research (ICMR).

Responding to another question, he said that the Delhi Development Authority (DDA) has agreed in principle for allotment of additional land for expansion of trauma centre at AIIMS.

Approximately, 185 cases are received every day in Jai Prakash Narayan Apex Trauma Centre of AIIMS, which has bed strength of 186, he added.

0 comments on “SC dismisses Bayer plea against generic drug—-Another indication that the Indian geographies are different and need a different approach, may be an Impact marketing!”

SC dismisses Bayer plea against generic drug—-Another indication that the Indian geographies are different and need a different approach, may be an Impact marketing!

MUMBAI: In a move which will bring cheer to patients and generic companies pursuing affordable treatments, the Supreme Court on Friday dismissed Bayer’s appeal on the compulsory licence (CL) issued on kidney and cancer drug, Nexavar. The Supreme Court set aside the special leave petition filed by the MNC in October against the Bombay high court’s decision upholding the CL on Nexavar, legal sources told TOI.

1 comment on “Sugar, Not Salt, May Be at Fault for Hypertension”

Sugar, Not Salt, May Be at Fault for Hypertension

Experts from an article by Lara C. Pullen, PhD December 11, 2014

A reduction in the consumption of added sugars and, in particular, processed foods may translate into decreased rates of hypertension as well as decreased cardiometabolic disease. In particular, a new review article suggests that sugar, not salt, appears to contribute to the majority of the hypertension risk associated with processed food.

0 comments on “13 Diabetes Myths that Don’t Lower Blood Sugar | Diabetic Living Online”

13 Diabetes Myths that Don’t Lower Blood Sugar | Diabetic Living Online

13 Diabetes Myths that Don’t Lower Blood Sugar | Diabetic Living Online.

Nothing trumps a balanced meal plan, an active lifestyle, and diabetes medications as needed to keep your blood glucose levels in check. You might have considered other diabetes remedies to try to lower blood sugar. Find out what works and what you should avoid.

0 comments on “New test to detect breast cancer”

New test to detect breast cancer

New test to detect breast cancer

New test to detect breast cancer

 

WASHINGTON:  A new study has revealed that breast cancer can be diagnosed early by detecting changes in the zinc in our bodies through a simple blood test.

Study conducted at Oxford University examined the techniques to analyse trace metal isotopes for studying climate change and planetary formation and then they applied them to how the human body processes metals.
For the first time in the history the researchers were able to show that changes in the isotopic composition of zinc, which can be detected in a person’s breast tissue, could make it possible to identify a “biomarker,” which was used to measure breast cancer.
Dr Fiona Larner of Oxford University’s Department of Earth Sciences said that it had been known for over a decade that breast cancer tissues contain high concentrations of zinc but the exact molecular mechanisms that might cause this have remained a mystery.
She further added that this research was the beginning of a whole new approach and to understand how different cancers have different trace metals and could enable them to develop both new diagnostic tools and new treatments.
The study is published in the Royal Society of Chemistry journal Metallomics. ANI

0 comments on “Senior Citizen alert Who are taking (ACE) inhibitor or an angiotensin receptor blocker (ARB) hypertension drugs!”

Senior Citizen alert Who are taking (ACE) inhibitor or an angiotensin receptor blocker (ARB) hypertension drugs!

Please note that all elder persons who are taking the above may have a problem with c-administration of this antibacterial drug called as Trimethoprim-sulfamethoxazole combination.
While trimethoprim-sulfamethoxazole (TMP-SMX) has generally been felt to be well tolerated, a case-control study found an association between sudden death, possibly due to hyperkalemia, and prescription of TMP-SMX among older patients who were also receiving an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB).

Hypertension has been well studied and reported in the setting of other cancer therapies. The importance of adequately diagnosing and managing hypertension in patient population arises from the facts that hypertension is well established as a risk factor for chemotherapy-induced cardiotoxicity and that poorly controlled hypertension can significantly influence cancer management and even lead to the discontinuation of certain therapies. Thanks

0 comments on “On Cancer: Soy Consumption May Promote Overexpression of Breast Cancer Genes in Some Women | Memorial Sloan Kettering Cancer Center”

On Cancer: Soy Consumption May Promote Overexpression of Breast Cancer Genes in Some Women | Memorial Sloan Kettering Cancer Center

By Jennifer Castoro, BA, Managing/Copy Editor  |  Thursday, September 4, 2014

Soy and products made from it, like soy milk and tofu, could have an effect on genes involved in breast cancer growth.Soy and products made from it, like soy milk and tofu, could have an effect on genes involved in breast cancer growth.

Theories abound as to which foods help or hurt in preventing cancer or easing its effects on the body. Researchers at Memorial Sloan Kettering have recently uncovered evidence that addresses one often-discussed food in many diets: soy.

On Cancer: Soy Consumption May Promote Overexpression of Breast Cancer Genes in Some Women | Memorial Sloan Kettering Cancer Center.

0 comments on “Ginger did it again! This time the working of this may not be very good to hear! read through the post and you would know of the bleeding aspects it may have due to dose and concentration of the extract or the like mixtures.”

Ginger did it again! This time the working of this may not be very good to hear! read through the post and you would know of the bleeding aspects it may have due to dose and concentration of the extract or the like mixtures.

Ginger for Preventing Chemo-Induced Nausea: What Is the Evidence?

Christine M. Walko, PharmD, BCOP

One of the more frequent questions I am asked by patients is whether they can continue to take, or should start taking, certain vitamins, herbals, or other complementary medications with their cancer therapy. It is estimated that at least 60% of cancer patients engage in complementary or alternative medical practices and with an increase in availability of both products and information, this is likely on the rise. Limitations in quality literature and concerns over lack of US Food and Drug Administration (FDA) oversight, along with questionable product purity and accurate labeling, have made many healthcare professionals rightfully hesitant to make helpful recommendations to patients beyond “use at your own risk.”

Two of the trials were negative in terms of benefit, two determined ginger was similar in benefit to metoclopramide, and three trials demonstrated some benefits.

0 comments on “Working Group Evaluates Designing Clinical Trials in Biomarker and Targeted Therapy Era – AACC.org”

Working Group Evaluates Designing Clinical Trials in Biomarker and Targeted Therapy Era – AACC.org

Oncology-related clinical trials fail more often than trials focused on other diseases

Working Group Evaluates Designing Clinical Trials in Biomarker and Targeted Therapy Era – AACC.org.

Oncology-related clinical trials fail more often than trials focused on other diseases, often during phase III, when much time and money has already been devoted to the research. The “heterogeneity of cancer across and within a disease” is likely one of the reasons these trials fail, says a report from the National Comprehensive Cancer Network (NCCN) Working Group on Clinical Trial Design in the Era of Multiple Biomarkers and Targeted Therapies, which offers recommendations for improving the clinical trial process.